Prove its efficacy and safety first


(FILES) In this file photo taken on October 17, 2018, a marijuana plant is pictured in Vancouver, Canada. - Canadian cannabis producer Aphria on Friday, December 28, 2018 rejected a proposed Can2.8 billion (2.1 billion US) takeover bid by US-based Xanthic Biopharma, calling it hostile and under-valued. Green Growth Brands, a division of Xanthic Biopharma, presented a conditional offer of Can11 per share on December 27, 2018 after markets closed. (Photo by Don MacKinnon / AFP)

THE Star Online last week reported the Deputy Health Minister of Malaysia’s response to Thailand approving marijuana for medical use and research (tinyurl.com/star-cannabis). Marijuana is also known as cannabis, or ganja in Malay.

Accor­ding to Deputy Minister Dr Lee Boon Chye, pharmaceutical firms wishing to register the drug for such use must provide the required standard information on its quality, efficacy and safety.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Letters

What Malaysia can learn from Gen Z
Display bus schedules at bus stops
Embracing the circular economy
Last chance to get plastics treaty right
Don’t jail them, make them work
We need to listen to children
Foreign worker problem in Penang
We need to manage waste better
Catalyst for public service reformation
Importance of securing loads on the road

Others Also Read